Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
The annual meeting is scheduled for December 10, 2024, with voting on director elections, executive compensation, and auditor ratification.
Shareholders can vote online, by phone, or by mail, with detailed instructions provided for each method.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact.
The Board recommends voting for all director nominees, for executive compensation, and for auditor ratification.
Voting matters and shareholder proposals
Four Class III directors are nominated for election to serve until the 2027 annual meeting.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of KPMG LLP as auditors for the year ending December 31, 2024.
Shareholders may submit proposals or director nominations for the 2025 annual meeting, following advance notice and procedural requirements.
Board of directors and corporate governance
The Board consists of a majority of independent directors, with a lead independent director appointed due to the CEO also serving as Chair.
Board committees include audit, compensation, nominating and corporate governance, and research and development, each with independent members.
Board diversity is considered in nominations, with recent appointments reflecting a commitment to diverse backgrounds.
Directors are elected to staggered three-year terms, supporting continuity and stability.
Latest events from Zymeworks
- Strategy targets royalty growth, $440M milestones, and $125M share buyback for long-term value.ZYME
Investor Update9 Jul 2026 - Zanidatamab advances globally as cash of $395.9M supports a strong pipeline and narrowed losses.ZYME
Q2 20248 Jul 2026 - Q1 2025 revenue surged 171% on milestones; cash runway extends into 2H-2027.ZYME
Q1 20258 Jul 2026 - Acquisition adds YUPELRI®, diversified assets, and tax benefits, boosting cash flow and value.ZYME
M&A announcement29 Jun 2026 - Zanidatamab nears approval as pipeline assets advance and R&D shifts to novel multi-specifics.ZYME
Jefferies Global Healthcare Conference 20264 Jun 2026 - Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026 - Virtual annual meeting on Dec 30, 2025, covers director elections, pay, and auditor ratification.ZYME
Proxy filing18 May 2026